RxDoctor Payments Data

John Yordy

Radiation Oncology · Palmer, AKNPI 1063711026

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 12 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by AstraZeneca at 28.6% of the total.

$1,055in general payments, 2019–2025

Across 12 payments — averaging $87.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$302
  • Novocure Inc.$246
  • Elekta, Inc.$213
  • Boston Scientific$164
  • Merck$129

What the payments were for

  • Food & beverage$1,055100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca3$302
Novocure Inc.3$246
Elekta, Inc.2$213
Boston Scientific3$164
Merck1$129

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few radiation oncology providers in Alaskato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$1,007,476
Medicare patients
230
Services billed
5,747

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other radiation oncology in Palmer

See the full list for Alaska

Where these figures come from

Is this you, or does something look wrong? →